Ozempic Linked to 70% Lower Alzheimer's Risk in Type 2 Diabetes Patients

Oct 24, 2024, 12:14 PM

Novo Nordisk's diabetes drug Ozempic, which contains the active ingredient semaglutide, has been linked to a significantly reduced risk of being diagnosed with Alzheimer's disease among people with type 2 diabetes. The observational study found a 70% lower risk of Alzheimer's diagnosis compared to other diabetes medications, based on an analysis of medical records. This adds to the growing evidence of Ozempic's effects beyond type 2 diabetes and obesity, indicating potential benefits in neurodegenerative diseases. Wegovy, another drug containing semaglutide, may also reduce Alzheimer's risk.